On January 26th, KBIC hosted "Regenerative Medicine Industrialization Forum 2024 in Nihonbashi" together with City of Kobe, IQVIA Services Japan Ltd. and Life Science Innovation Network Japan (Link-J) in Tokyo. This event aims to share common issues and challenges among companies, research institutions and academia, promoting mutual collaboration to accelerate industrialization of Regenerative Medicine field. On the day of event, approximately 750 people (onsite + online) attended and learned about the latest developments in the area of cell and gene therapy.
At this seventh series of Regenerative Medicine Industrialization Forum, a couple of speeches such as researchers from Kyoto University iPS Research Institute and pharmaceutical companies introduced their latest efforts under the theme of "Creating Innovation for the Future of Regenerative Medicine, Cell Therapy, and Gene Therapy Industries”. At the panel discussion, there was a discussion on how to further accelerate the development process and establish solid pathway towards the industrialization given the fact that many of the seeds have already been put into commercial production.
During networking time, speakers and audience spent valuable time communicating and socializing, meeting new people and had a wonderful time!
Regenerative Here’s links to some of the scenes from the forum!
＊Please set your YouTube subtitle setting in English if necessary.
「Introduction of Kobe Biomedical Innovation Cluster (KBIC) 」
Kozo Mori, Director, Biomedical Innovation Cluster Department, City of Kobe
URL: https://youtu.be/sbqEWNREYWQ
「Strategic Priorities for Designing a Process for Commercialization」
Mark J Santos, Global Head of Commercial Development and Marketing, Lonza
URL: https://youtu.be/9XX0G4a_3lI
Closing Remarks
Akihiko Soyama, CEO, Life Science Innovation Network Japan
URL: https://youtu.be/Vb5v1e2MnsA
【Regenerative Medicine Industrialization Forum 2024 in Nihonbashi】
URL: https://www.fbri-kobe.org/kbic/event/detail.php?event_id=684
(This site is only in Japanese)